| 2024 | Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
| ONCOLOGIST |
| 2024 | Nuclear Localization of Yes-Associated Protein Is Associated With Tumor Progression in Cutaneous Melanoma
| LABORATORY INVESTIGATION |
| 2024 | Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
| EUROPEAN UROLOGY |
| 2023 | Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) | CLINICAL CANCER RESEARCH |
| 2023 | Active involvement of patients, radiation oncologists, and surgeons in a multidisciplinary team approach: Guiding local therapy in recurrent, metastatic rectal cancer
| CANCER MEDICINE |
| 2023 | A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)
| EUROPEAN JOURNAL OF CANCER |
| 2023 | A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
| INVESTIGATIVE AND CLINICAL UROLOGY |
| 2023 | A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer | CLINICAL CANCER RESEARCH |
| 2023 | Effect of High-Versus Low-Frequency of Abdominopelvic Computed Tomography Follow-Up Testing on Overall Survival in Patients With Stage II Or III Colon Cancer | CLINICAL COLORECTAL CANCER |
| 2023 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
| ESMO OPEN |
| 2023 | Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study – (NCT05103020) – study protocol
| BMC CANCER |
| 2023 | Importance of Local Ablative Therapies for Lung Metastases in Patients With Colorectal Cancer | ANNALS OF SURGERY |
| 2023 | Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study
| CANCER RESEARCH AND TREATMENT |
| 2023 | Short-Term Outcomes and Cost-Effectiveness between Long-Course Chemoradiation and Short-Course Radiotherapy for Locally Advanced Rectal Cancer
| YONSEI MEDICAL JOURNAL |
| 2023 | Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic disease
| FRONTIERS IN ONCOLOGY |
| 2023 | Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
| ESMO OPEN |
| 2023 | Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy
| CANCER RESEARCH AND TREATMENT |
| 2023 | Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers
| FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY |
| 2023 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2023 | Machine Learning-Based Mortality Prediction Model for Critically Ill Cancer Patients Admitted to the Intensive Care Unit (CanICU)
| CANCERS |
| 2022 | A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2022 | Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Feasibility of using dental putty-based custom molds for high-dose-rate brachytherapy of oral mucosal melanoma | PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS |
| 2022 | First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY |
| 2022 | A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13) | EUROPEAN JOURNAL OF CANCER |
| 2022 | Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure | EUROPEAN JOURNAL OF CANCER |
| 2022 | The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
| ESMO OPEN |
| 2022 | Periodontal disease and cancer risk: A nationwide population-based cohort study
| FRONTIERS IN ONCOLOGY |
| 2022 | KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1 + stem cells
| CELL REPORTS |
| 2022 | The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Application of Multigene Panel Testing in Patients With High Risk for Hereditary Colorectal Cancer: A Descriptive Report Focused on Genotype-Phenotype Correlation | DISEASES OF THE COLON & RECTUM |
| 2022 | Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer | CLINICAL COLORECTAL CANCER |
| 2022 | Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
| CANCERS |
| 2022 | Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer
| RADIATION ONCOLOGY |
| 2022 | Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
| EUROPEAN JOURNAL OF CANCER |
| 2022 | First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells | ANTICANCER RESEARCH |
| 2021 | Deep-Learning-Based Natural Language Processing of Serial Free-Text Radiological Reports for Predicting Rectal Cancer Patient Survival
| FRONTIERS IN ONCOLOGY |
| 2021 | Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases | EJSO |
| 2021 | A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2021 | Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma
| CANCER RESEARCH AND TREATMENT |
| 2021 | Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS |
| 2021 | Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection
| WORLD ALLERGY ORGANIZATION JOURNAL |
| 2021 | Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View
| YONSEI MEDICAL JOURNAL |
| 2021 | ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | NATURE |
| 2021 | The Awareness and Usage of Big Data for Cancer in Korea: A Survey Study
| Journal of Health Informatics and Statistics(보건정보통계학회지) |
http://orcid.org/0000-0001-5350-7241
(7403647334)
